← Back to Discover
MPM BioImpact LLC
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $1,639,957,110
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Cullinan Therapeutics, Inc. · 230031106 · 230031106 · shares: $177,207,720
- Aktis Oncology, Inc. · 01021M104 · 01021M104 · shares: $155,860,155
- Liquidia Corporation · 53635D202 · 53635D202 · shares: $110,519,653
- Revolution Medicines, Inc. · 76155X100 · 76155X100 · shares: $92,232,216
- Corcept Therapeutics, Inc. · 218352102 · 218352102 · shares: $67,040,885
- Edgewise Therapeutics Inc · 28036F105 · 28036F105 · shares: $65,852,291
- Travere Therapeutics Inc · 89422G107 · 89422G107 · shares: $63,782,348
- DBV Technologies S A · 23306J309 · 23306J309 · shares: $60,127,058
- Trevi Therapeutics Inc · 89532M101 · 89532M101 · shares: $57,322,211
- Alumis Inc · 022307102 · 022307102 · shares: $56,815,223
Reported holdings
37 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. | 230031106 | 230031106 | — | 9,731,341 shares | $177,207,720 |
| Aktis Oncology, Inc. | 01021M104 | 01021M104 | — | 4,835,872 shares | $155,860,155 |
| Liquidia Corporation | 53635D202 | 53635D202 | — | 1,386,174 shares | $110,519,653 |
| Revolution Medicines, Inc. | 76155X100 | 76155X100 | — | 492,483 shares | $92,232,216 |
| Corcept Therapeutics, Inc. | 218352102 | 218352102 | — | 771,028 shares | $67,040,885 |
| Edgewise Therapeutics Inc | 28036F105 | 28036F105 | — | 1,620,780 shares | $65,852,291 |
| Travere Therapeutics Inc | 89422G107 | 89422G107 | — | 1,122,731 shares | $63,782,348 |
| DBV Technologies S A | 23306J309 | 23306J309 | — | 3,666,284 shares | $60,127,058 |
| Trevi Therapeutics Inc | 89532M101 | 89532M101 | — | 3,073,577 shares | $57,322,211 |
| Alumis Inc | 022307102 | 022307102 | — | 2,019,020 shares | $56,815,223 |
| Uniqure NV | N90064101 | N90064101 | — | 1,225,855 shares | $56,462,881 |
| Ultragenyx Pharmaceuticals, Inc. | 90400D108 | 90400D108 | — | 1,418,215 shares | $47,354,199 |
| Relay Therapeutics Inc. | 75943R102 | 75943R102 | — | 2,415,672 shares | $45,197,223 |
| Abivax SA | 00370M103 | 00370M103 | — | 336,347 shares | $44,821,601 |
| Dyne Therapeutics, Inc. | 26818M108 | 26818M108 | — | 1,922,093 shares | $42,689,686 |
| Dianthus Therapeutics Inc | 252828108 | 252828108 | — | 420,002 shares | $40,941,795 |
| BIOAGE Labs Inc | 09077V100 | 09077V100 | — | 1,667,661 shares | $40,874,371 |
| Urogen Pharma Ltd | M96088105 | M96088105 | — | 933,415 shares | $34,349,672 |
| MoonLake Immunotherapeutics | 61559X104 | 61559X104 | — | 1,606,967 shares | $31,287,647 |
| Palvella Therapeutics Inc | 697947109 | 697947109 | — | 204,027 shares | $31,179,406 |
| Taysha Gene Therapies, Inc. | 877619106 | 877619106 | — | 4,500,000 shares | $30,645,000 |
| Syndax Pharmaceuticals Inc | 87164F105 | 87164F105 | — | 1,333,523 shares | $29,150,813 |
| Monte Rosa Therapeutics Inc | 61225M102 | 61225M102 | — | 1,161,081 shares | $28,098,160 |
| Zura Bio Ltd. | G9TY5A101 | G9TY5A101 | — | 4,472,843 shares | $26,389,774 |
| Natera Inc | 632307104 | 632307104 | — | 92,638 shares | $25,146,585 |
| Stoke Therapeutics Inc | 86150R107 | 86150R107 | — | 723,314 shares | $23,666,834 |
| Adlai Nortye Ltd | 00704R109 | 00704R109 | — | 1,936,291 shares | $22,267,347 |
| Belite Bio Inc | 07782B104 | 07782B104 | — | 137,208 shares | $21,127,974 |
| Forte Biosciences, Inc. | 34962G208 | 34962G208 | — | 987,448 shares | $20,983,270 |
| Oric Pharmaceuticals Inc | 68622P109 | 68622P109 | — | 1,882,162 shares | $20,383,814 |
| Tarsus Pharmaceuticals Inc | 87650L103 | 87650L103 | — | 322,007 shares | $20,267,121 |
| Annexon Inc | 03589W102 | 03589W102 | — | 3,544,354 shares | $20,238,261 |
| Bright Minds Biosciences Inc | 10919W405 | 10919W405 | — | 202,114 shares | $14,188,403 |
| Entrada Therapeutics, Inc. | 29384C108 | 29384C108 | — | 1,253,053 shares | $9,222,470 |
| Aclaris Therapeutics Inc | 00461U105 | 00461U105 | — | 1,042,467 shares | $5,514,650 |
| Context Therapeutics Inc | 21077P108 | 21077P108 | — | 1,299,046 shares | $719,542 |
| Werewolf Therapeutics, Inc. | 95075A107 | 95075A107 | — | 80,142 shares | $28,851 |